Iovance reports $485M cash, AMTAGVI launch ongoing; partial clinical hold on lung TIL trial

IOVANCE BIOTHERAPEUTICS, INC.

Cash position ~$485M as of 2/22/24, including $197.1M from Feb 2024 equity offering.
AMTAGVI (lifileucel) approved for advanced melanoma; 30 active ATCs at launch, targeting ~50 within 90 days.
FDA placed partial clinical hold on IOV-LUN-202 NSCLC trial on Dec 22, 2023; enrollment paused.
Phase 3 TILVANCE-301 frontline melanoma trial randomized first patient in 2Q23.
Proleukin acquired for £167.7M upfront; global rights secured for IL-2 supply in AMTAGVI regimen.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.